The addition of anti-HER-2 antibodies to conventional chemotherapy and/or immune checkpoint inhibitor in HER-2 positive resectable GC [31] are under investigation and the trial results will be reported in the near future. This evidence concerns the gene ERBB2 and gastric cancer.